Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer

Phase 3

Conditions: Colorectal Cancer

Interventions: Drug: fluorouracil
Drug: capecitabine
Radiation: radiation therapy
Drug: oxaliplatin

First Posted Date: 2003-04-09

Last Posted Date: 2016-03-23

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 1608

Registration Number: NCT00058474

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: capecitabine
Drug: docetaxel

First Posted Date: 2003-02-06

Last Posted Date: 2016-12-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 46

Registration Number: NCT00054457

Locations: 🇺🇸
Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States

and more 25 locations

Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

Phase 2

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: Pharmatech Oncology

Registration Number: NCT00026442

Locations: 🇺🇸
Hematology Oncology Associates of theTreasure Coast - Port St. Lucie, Port Saint Lucie, Florida, United States
🇺🇸
Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States
🇺🇸
Medical Oncology Care Associates, Orange, California, United States

and more 7 locations

Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Drug: capecitabine
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00043121

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-27

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00016926

Locations: 🇺🇸
Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

and more 7 locations

Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-26

Lead Sponsor: Cancer Research UK

Target Recruit Count: 508

Registration Number: NCT00032175

Locations: 🇬🇧
Singleton Hospital of the Swansea NHS Trust, Swansea, Wales, United Kingdom
🇬🇧
Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, England, United Kingdom
🇬🇧
Royal United Hospital, Bath, England, United Kingdom

and more 27 locations

Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 47

Registration Number: NCT00049660

Locations: 🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇧🇪
Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium

and more 9 locations

Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 34

Registration Number: NCT00031876

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
UniversitaetsSpital, Zurich, Switzerland

Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 110

Registration Number: NCT00003902

Locations: 🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

Phase 1

Completed

Conditions: Esophageal Cancer
Extrahepatic Bile Duct Cancer
Gastric Cancer
Head and Neck Cancer
Liver Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2012-03-08

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT00021047

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸
Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy